Eli Lilly Entered into a Research Collaboration and License Agreement with Nimbus Therapeutics for Small Molecule Activators of AMPK
Shots:
- Nimbus to receive ~$496M in research funding & milestones through research, development & commercialization along with royalties
- The collaboration will use Nimbus’s computational drug discovery engine & expertise in structure-based drug design to develop isoform-selective small molecule activators of AMPK against therapeutic targets for metabolic disorders
- Nimbus will lead the research activities while Lilly will be responsible for development & commercialization activities globally. The pipeline of Nimbus includes a variety of selective small-molecule drugs that target proteins recognized to be essential contributors to pathology in human disorders. These proteins have proven challenging for drug developers to target
Ref: Businesswire | Image: Eli Lilly
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
